CapVest closed the Stada Arzneimittel acquisition in late August for €5.3 billion enterprise value, making it Europe's largest leveraged buyout in 2025. The London-based mid-market firm beat Blackstone, KKR, and CVC on a pharmaceutical platform with €3.7 billion in annual revenue across 120 markets. The deal priced senior debt at EURIBOR plus 375 basis points and closed without covenant adjustments, a rarity in the current European syndication environment.
Stada manufactures generics, over-the-counter treatments, and specialty pharma across Western Europe and Russia. CapVest inherited a distribution network that moves 17 billion tablets annually and a brand portfolio with 40 percent market penetration in German OTC. The company generates 23 percent EBITDA margins on a cash-conversion cycle of 67 days, cleaner than most peer rollups. Management stays intact under CEO Peter Goldschmidt, who ran the prior integration of six bolt-ons between 2019 and 2023.
This marks CapVest's largest platform acquisition by a factor of three. The firm previously concentrated on €400 million to €1.2 billion EV targets in food manufacturing and specialty distribution. Stada required a €2.1 billion equity check and brought in co-investment from PSP Investments and a German family office that requested anonymity. The debt syndication took eleven weeks to clear, longer than the six-week average for mid-market European deals this year, reflecting hesitation around pharma supply-chain exposure to Eastern European manufacturing.
The acquisition matters because it demonstrates continued LP appetite for large European buyouts outside the established mega-funds. CapVest raised €3.8 billion for Fund VI in April, then deployed 55 percent of that capital on Stada alone. That level of concentration is unusual outside distressed or special-situations mandates. It also suggests that pharmaceutical platforms with diversified payor exposure and stable cash generation still command aggressive leverage multiples — Stada closed at 6.2 times net debt to EBITDA, in line with pre-pandemic norms.
Operators should watch Stada's Q4 2025 earnings release for any margin compression tied to generic-pricing pressure in Germany, where reimbursement cuts averaged 8 percent across the top twenty molecules this year. CapVest will likely announce at least one bolt-on acquisition by mid-2026, targeting either Iberian distribution or a Central European OTC brand with sub-€300 million revenue. The firm has historically moved quickly post-close, completing first add-ons within nine months on prior platforms.
The deal also resets valuation expectations for mid-tier European pharma. If CapVest can refinance Stada's debt stack at current spreads in eighteen months, it implies the high-yield market still prices pharmaceutical manufacturing as investment-grade risk despite supply-chain fragmentation. That assumption will be tested when the next wave of German generics repricings hits in Q2 2026.